Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor,Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid Malignancies

Tuesday, April 16, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: PRT2527, a selective CDK9 inhibitor, demonstrates significant antitumor effects when used in combination with BTK and BCL2 inhibitors. This combination therapy shows potential for treating various lymphoid malignancies, suggesting a new avenue for effective cancer treatment. The findings highlight the importance of targeting CDK9 in cancer therapy.
Price reaction · baseline $4.91 (2024-04-16 close) · hit after-hours · 2 other PRLD headline(s) in the window, move may be shared
day 0 close
-14.9%
day 1 · peak
-29.9%
day 3
-21.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • PRT2527 shows potent antitumor activity.
  • Combination therapy with BTK and BCL2 inhibitors is promising.
  • Targeting CDK9 may enhance treatment outcomes in lymphoid malignancies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

• About Overview Leadership Board of Directors
• Science Overview Pipeline JAK2V617F KAT6A Precision DACs Discovery Engine Publications
• Investors Overview News & Events News Releases Events & Presentations Financials SEC Filings Quarterly Results Stock Information Stock Quote & Chart Analysts Governance Governance Documents Leadership Committee Composition Investor Resources Investor Faqs Contact IR Email Alerts
• News
• Life at Prelude Overview Open Positions
• Contact
• Overview
• Leadership
• Board of Directors
• Overview
• Pipeline
• JAK2V617F
• KAT6A
• Precision DACs
• Discovery Engine
• Publications
• Overview
• News & Events News Releases Events & Presentations
• Financials SEC Filings Quarterly Results
• Stock Information Stock Quote & Chart Analysts
• Governance Governance Documents Leadership Committee Composition
• Investor Resources Investor Faqs Contact IR Email Alerts
• News Releases
• Events & Presentations
• SEC Filings
• Quarterly Results
• Stock Quote & Chart
• Analysts
• Governance Documents
• Leadership
• Committee Composition
• Investor Faqs
• Contact IR
• Email Alerts
• Overview
• Open Positions
Norman Fultang, Ashley Schwab, Sophia McAneny-Droz, Diane Heiser, Peggy Scherle, Neha Bhagwat

Frequently Asked Questions

What is PRT2527?

PRT2527 is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor.

How does PRT2527 work?

It shows potent antitumor activity, especially when combined with BTK and BCL2 inhibitors.

What types of cancer is PRT2527 targeting?

PRT2527 is being studied for its effects on various lymphoid malignancies.

What is the significance of CDK9 inhibition?

Inhibiting CDK9 may enhance treatment outcomes in cancer therapy.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT2527 CDK9 inhibitor BTK inhibitor BCL2 inhibitor lymphoid malignancies
Last updated: Apr 16, 2024

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →